Top Markets
#1 Islamic Coin Islamic Coin +154.47%
#2 PulseChain PulseChain +49.22%
#3 RedStone RedStone +22.21%
#4 BOOK OF MEME BOOK OF MEME +18.12%
#5 Starpower Starpower +14.19%
#6 Venom Venom +12.35%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.28%
#8 Lighter Lighter +12.26%
#9 Nockchain Nockchain +11.12%
#10 SkyAI SkyAI +10.56%
Coin of the day
Islamic Coin Islamic Coin
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Biocartis Group N.V. Biocartis Group N.V.

Biocartis Group N.V.

BCART
Rang in aandelen #27531
Biocartis Group NV is a molecular diagnostics firm dedicated to improving... Biocartis Group NV is a molecular diagnostics firm dedicated to improving clinical care. Its innovative diagnostic solutions primarily serve the oncology sector, benefiting patients, medical professionals, insurers, and the broader healthcare ecosystem. The company's cornerstone is its exclusive Idylla molecular diagnostics platform, a sophisticated real-time polymerase chain reaction (PCR) system. This technology delivers crucial molecular data, aiding in the selection of appropriate treatments and the continuous monitoring of patient progress. Biocartis offers a range of diagnostic tests via the Idylla system, including mutation analysis for BRAF, KRAS, MSI, EGFR, and NRAS-BRAF. Additionally, it provides Idylla panels for SARS-CoV-2/Flu/RSV, standalone SARS-CoV-2 tests, and the rapid host-response assessment, SeptiCyte RAPID. For research purposes, the company supplies various mutation assays, such as those for MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R. Biocartis has entered into strategic partnerships to broaden its impact. One such collaboration is with Amgen, focusing on evaluating Idylla RAS testing to enable swift, decentralized diagnostics and enhance the accessibility of RAS biomarker data through the Idylla platform and its associated RAS tests. Another key alliance is with Bristol-Myers Squibb Company, centered on the registration and application of the Idylla MSI test within the field of immuno-oncology treatments. Furthermore, a licensing, development, and commercialization agreement with GeneproDx is in place for the creation of the innovative ThyroidPrint genomic test, to be integrated onto the Idylla platform. Established in 2007, Biocartis maintains its corporate headquarters in Mechelen, Belgium.
Aandeelprijs
$0.343985
Laatst gesynchroniseerd: 2024-07-23
Marktkapitalisatie
$32.31M
Verandering (1 dag)
11.88%
Verandering (1 jaar)
0.00%
Land
BE
Handel Biocartis Group N.V. (BCART)

Categorie

Healthcare
Dividendgeschiedenis van Biocartis Group N.V. (BCART)
Biocartis Group N.V. (aandelsymbool: BCART) heeft in totaal 0 dividenduitkeringen gedaan.
De som van alle dividenden (aangepast voor aandelensplitsingen) is: 0.00
Dividendrendement (TTM): 0
Dividendbetalingen voor Biocartis Group N.V. (BCART) van 2026 tot 2026
Jaarlijkse dividendbetalingen
Jaar Dividend (aangepast voor aandelensplitsingen) Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Lijst van alle dividendbetalingen
Jaar Dividend Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendbetalingen voor vergelijkbare bedrijven of concurrenten
Bedrijf Aantal dividendbetalingen Land
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
60.00%
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
134.00%
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
0.00%
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
0.00%
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
0.00%
US